-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The research reports of securities companies have always attracted the attention of investors.
From the research reports, investors can quickly understand an industry, timely obtain analysts' interpretations of the performance of related companies, and understand market changes and investment trends
.
Since March, a number of pharmaceutical equipment companies have received the attention of research reports from securities companies, including Chutian Technology, Tofflon, and Chengyitong
.
Since March, a number of pharmaceutical equipment companies have received the attention of securities companies' research reports (Source: Pharmaceutical Network) Tofflon Debon Securities released a research report on March 29, giving Tofflon a buy rating
.
The reasons for the rating mainly include three aspects: first, it has been deeply cultivated for nearly 30 years, and it has built a leading domestic pharmaceutical equipment enterprise; second, the domestic biopharmaceutical industry is thriving, opening the ceiling of the pharmaceutical equipment industry; third, the products and channels are combined, and Dongfu Long is expected to become a platform-based enterprise for the industrialization of biological drugs
.
Risk warning: The risk of industry prosperity decline; product volume is lower than expected; product export is lower than expected
.
According to statistics, Tofflon has received the attention of 3 brokerage research reports from Debon Securities, Zheshang Securities and Guosheng Securities in the past month, of which 2 Debon Securities and Guosheng Securities bought and 1 Zheshang Securities increased their holdings
.
Chengyitong On March 9, Tianfeng Securities released the report "One Body with Two Wings, Medical Intelligent Manufacturing and Two-Wheel Drive for Rehabilitation Equipment", giving Chengyitong a "buy" rating
.
The reasons for the rating mainly include: the rehabilitation business policy encourages, focusing on the grassroots, and the development is expected; the pharmaceutical intelligent manufacturing business is generally stable
.
Risk warning: Risks of fluctuations in the performance of the pharmaceutical intelligent manufacturing business, risks of lower-than-expected sales of rehabilitation equipment, risks of repeated epidemics, lower-than-expected policy implementation, and intensified market competition
.
In the past month, Chengyitong has received a total of 1 securities company research report and bought 1
.
Chutian Technology On March 12, Caitong Securities released a research report, giving Chutian Technology a “buy” investment rating
.
The brokerage believes that in the long run, although Chutian Technology's vaccine-related income has declined, overseas business layout, biopharmaceutical-related equipment and traditional Chinese medicine production-related equipment will become new profit points
.
The reasons for the rating mainly include several points: First, the acquisition of Romaco shows synergistic effects, and international business can help to stabilize the domestic industry cycle; second, biopharmaceutical-related equipment expands into new categories, domestic substitution is gradually accepted and superimposed technology accumulation, Chutian Siyoute , Chutian Yuanchuang and Chutian Microspheres are expected to contribute new growth points; thirdly, "pharmaceutical intelligent manufacturing" is the only way for traditional Chinese medicine to move towards a modern industry.
With the increase in industry concentration brought about by the current round of traditional Chinese medicine modernization
.
Risk reminder: the risk of new product development not meeting expectations; exchange rate fluctuation risk; goodwill impairment risk; exchange rate fluctuation risk; overseas market expansion less than expected risk; commodity price fluctuation risk
;
In the past month, Chutian Technology has received 1 research report from securities companies and bought 1
.
Conclusion It is said that the research report has its own "Golden House", and the research report has its own "Strategy Book"
.
Judging from the forecast and analysis of the above-mentioned pharmaceutical equipment companies by securities companies, many securities companies still pay attention to the representative companies in the pharmaceutical machine industry
.
Pharmaceutical equipment belongs to the upstream of the pharmaceutical industry.
In recent years, the biopharmaceutical and traditional Chinese medicine industries have been driven by favorable policies, consumption upgrades, and intelligent pharmaceutical manufacturing.
They have broad prospects in the future, bringing opportunities to the leading companies in the pharmaceutical equipment industry and replacing domestic pharmaceutical equipment imports.
Under the background of accelerated pace and international layout, leading companies in the industry are more likely to benefit
.
Of course, the research report also pointed out some risks, such as new product development less than expected, industry prosperity, product export less than expected and other risks, investors need to be cautious
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
From the research reports, investors can quickly understand an industry, timely obtain analysts' interpretations of the performance of related companies, and understand market changes and investment trends
.
Since March, a number of pharmaceutical equipment companies have received the attention of research reports from securities companies, including Chutian Technology, Tofflon, and Chengyitong
.
Since March, a number of pharmaceutical equipment companies have received the attention of securities companies' research reports (Source: Pharmaceutical Network) Tofflon Debon Securities released a research report on March 29, giving Tofflon a buy rating
.
The reasons for the rating mainly include three aspects: first, it has been deeply cultivated for nearly 30 years, and it has built a leading domestic pharmaceutical equipment enterprise; second, the domestic biopharmaceutical industry is thriving, opening the ceiling of the pharmaceutical equipment industry; third, the products and channels are combined, and Dongfu Long is expected to become a platform-based enterprise for the industrialization of biological drugs
.
Risk warning: The risk of industry prosperity decline; product volume is lower than expected; product export is lower than expected
.
According to statistics, Tofflon has received the attention of 3 brokerage research reports from Debon Securities, Zheshang Securities and Guosheng Securities in the past month, of which 2 Debon Securities and Guosheng Securities bought and 1 Zheshang Securities increased their holdings
.
Chengyitong On March 9, Tianfeng Securities released the report "One Body with Two Wings, Medical Intelligent Manufacturing and Two-Wheel Drive for Rehabilitation Equipment", giving Chengyitong a "buy" rating
.
The reasons for the rating mainly include: the rehabilitation business policy encourages, focusing on the grassroots, and the development is expected; the pharmaceutical intelligent manufacturing business is generally stable
.
Risk warning: Risks of fluctuations in the performance of the pharmaceutical intelligent manufacturing business, risks of lower-than-expected sales of rehabilitation equipment, risks of repeated epidemics, lower-than-expected policy implementation, and intensified market competition
.
In the past month, Chengyitong has received a total of 1 securities company research report and bought 1
.
Chutian Technology On March 12, Caitong Securities released a research report, giving Chutian Technology a “buy” investment rating
.
The brokerage believes that in the long run, although Chutian Technology's vaccine-related income has declined, overseas business layout, biopharmaceutical-related equipment and traditional Chinese medicine production-related equipment will become new profit points
.
The reasons for the rating mainly include several points: First, the acquisition of Romaco shows synergistic effects, and international business can help to stabilize the domestic industry cycle; second, biopharmaceutical-related equipment expands into new categories, domestic substitution is gradually accepted and superimposed technology accumulation, Chutian Siyoute , Chutian Yuanchuang and Chutian Microspheres are expected to contribute new growth points; thirdly, "pharmaceutical intelligent manufacturing" is the only way for traditional Chinese medicine to move towards a modern industry.
With the increase in industry concentration brought about by the current round of traditional Chinese medicine modernization
.
Risk reminder: the risk of new product development not meeting expectations; exchange rate fluctuation risk; goodwill impairment risk; exchange rate fluctuation risk; overseas market expansion less than expected risk; commodity price fluctuation risk
;
In the past month, Chutian Technology has received 1 research report from securities companies and bought 1
.
Conclusion It is said that the research report has its own "Golden House", and the research report has its own "Strategy Book"
.
Judging from the forecast and analysis of the above-mentioned pharmaceutical equipment companies by securities companies, many securities companies still pay attention to the representative companies in the pharmaceutical machine industry
.
Pharmaceutical equipment belongs to the upstream of the pharmaceutical industry.
In recent years, the biopharmaceutical and traditional Chinese medicine industries have been driven by favorable policies, consumption upgrades, and intelligent pharmaceutical manufacturing.
They have broad prospects in the future, bringing opportunities to the leading companies in the pharmaceutical equipment industry and replacing domestic pharmaceutical equipment imports.
Under the background of accelerated pace and international layout, leading companies in the industry are more likely to benefit
.
Of course, the research report also pointed out some risks, such as new product development less than expected, industry prosperity, product export less than expected and other risks, investors need to be cautious
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
